Related Experiment Video

Updated: Jun 24, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

A Oden-Gangloff1, F Di Fiore, F Bibeau

  • 1Inserm U614, Faculty of Medicine, Institute for Biomedical Research, University of Rouen, Rouen, France.

British Journal of Cancer
|April 16, 2009
PubMed

Insights

TP53 mutations predict better response to cetuximab chemotherapy in metastatic colorectal cancer. This finding is especially relevant for patients without KRAS mutations, suggesting TP53 genotyping for treatment selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Epidermal Growth Factor Receptor (EGFR) pathway activation is linked to cancer, but its oncogenic potential may depend on p53 protein status.
  • KRAS mutations are known predictors of resistance to cetuximab, a targeted therapy.
  • The role of TP53 mutations in modulating cetuximab sensitivity, especially in conjunction with KRAS status, requires further elucidation.

Purpose of the Study:

  • To investigate the impact of TP53 mutations on the efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC).
  • To assess the combined effect of TP53 and KRAS mutations on cetuximab treatment outcomes.
  • To determine if TP53 genotyping can aid in selecting mCRC patients who may benefit from cetuximab therapy.

Main Methods:

  • Tumor samples from 64 mCRC patients treated with cetuximab-based chemotherapy were analyzed for KRAS and TP53 mutational status.
  • Clinical response was correlated with gene status using Fisher's exact test.
  • Times to Progression (TTP) were calculated using Kaplan-Meier analysis and compared via log-rank test.

Main Results:

  • TP53 mutations were identified in 41 patients and were significantly associated with Controlled Disease (CD) and longer TTP (20 vs 12 weeks).
  • In patients without KRAS mutations (n=46), TP53 mutations showed a stronger association with CD and significantly higher TTP (24 vs 12 weeks).
  • No significant association between TP53 mutations and outcomes was observed in patients with KRAS mutations.

Conclusions:

  • TP53 mutations appear to be a predictive biomarker for improved sensitivity to cetuximab-based chemotherapy in mCRC.
  • The predictive value of TP53 mutations is particularly pronounced in the subset of patients lacking KRAS mutations.
  • TP53 genotyping may offer clinical utility in personalizing cetuximab treatment strategies for mCRC patients.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...